An Observational National Pediatric Study on Prevalence of Unexplained Splenomegaly

Status: Completed
Location: See all (40) locations...
Study Type: Observational
SUMMARY

Objective: To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology). Secondary

Objectives: * To describe the rate of each identified disease category and the rate of patients with no final diagnosis at the end of the study in pediatric patients with unexplained SMG after exclusion of first intention diagnoses * To describe the characteristics (clinical, lab, genetics) of all pediatric patients included in the study and to describe the characteristics subdivided by identified disease category and absence of final diagnosis at the end of the study

Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:

• Patient under the age of 18 years

• Patient with unexplained SMG (SMG defined as a palpable spleen, already known or discovered for the first time) and who has undergone tests to eliminate obvious causes of SMG

Locations
Other Locations
France
Investigational Site Number 2500036
Amiens
Investigational Site Number 2500014
Angers
Investigational Site Number 2500034
Argenteuil
Investigational Site Number 2500039
Bayonne
Investigational Site Number 2500015
Besançon
Investigational Site Number 2500003
Bordeaux
Investigational Site Number 2500038
Brest
Investigational Site Number 2500026
Caen
Investigational Site Number 2500018
Chambéry
Investigational Site Number 2500009
Clermont-ferrand
Investigational Site Number 2500008
Colombes
Investigational Site Number 2500028
Créteil
Investigational Site Number 2500006
Dijon
Investigational Site Number 2500010
Gleizé
Investigational Site Number 2500031
Jossigny
Investigational Site Number 2500040
La Rochelle
Investigational Site Number 2500007
La Tronche
Investigational Site Number 2500030
Limoges
Investigational Site Number 2500001
Lyon
Investigational Site Number 2500032
Mantes-la-jolie
Investigational Site Number 2500005
Marseille
Investigational Site Number 2500027
Meaux
Investigational Site Number 2500002
Montpellier
Investigational Site Number 2500021
Nantes
Investigational Site Number 2500019
Nice
Investigational Site Number 2500022
Nîmes
Investigational Site Number 2500016
Paris
Investigational Site Number 2500013
Perpignan
Investigational Site Number 2500035
Poissy
Investigational Site Number 2500011
Poitiers
Investigational Site Number 2500029
Reims
Investigational Site Number 2500023
Rennes
Investigational Site Number 2500037
Roubaix
Investigational Site Number 2500024
Rouen
Investigational Site Number 2500017
Saint-priest-en-jarez
Investigational Site Number 2500004
Strasbourg
Investigational Site Number 2500033
Toulouse
Investigational Site Number 2500020
Tours
Investigational Site Number 2500025
Valenciennes
Investigational Site Number 2500012
Vandœuvre-lès-nancy
Time Frame
Start Date: 2021-06-30
Completion Date: 2024-11-25
Participants
Target number of participants: 60
Treatments
Pediatric Patients with Unexplained Enlarged Spleen
Sponsors
Leads: Sanofi

This content was sourced from clinicaltrials.gov